Oxandrolone treatment in adults with severe thermal injury

Pharmacotherapy

Volumn 29, Issue 2, 2009, Pages 213-226

  Miller, James T ^a   Btaiche, Imad F ^b,c  

^a SINAI GRACE HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Adults; Burn; Oxandrolone; Thermal injury

Indexed keywords

AMINO ACID; HUMAN GROWTH HORMONE; HYDROCORTISONE; INSULIN; OXANDROLONE; PLACEBO; PROPRANOLOL DERIVATIVE; RECOMBINANT SOMATOMEDIN C; TESTOSTERONE ENANTATE;

ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHAVIOR CHANGE; BILIRUBIN BLOOD LEVEL; BLADDER IRRITATION; BONE DEFORMATION; BURN; CLINICAL TRIAL; CLITORIS; CONTINUOUS INFUSION; DEPRESSION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ELECTROLYTE DISTURBANCE; ENTERIC FEEDING; EPIPHYSIS INJURY; EXCITATION; EXERCISE; FLUID RETENTION; HEART FAILURE; HIRSUTISM; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERMETABOLISM; HYPERTENSION; HYPOGLYCEMIA; INFECTION; INSOMNIA; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY FUNCTION; LEAN BODY WEIGHT; LENGTH OF STAY; LIPID METABOLISM; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; MENSTRUAL IRREGULARITY; MUSCLE STRENGTH; NITROGEN BALANCE; NUTRITIONAL SUPPORT; OBSTRUCTIVE JAUNDICE; PARENTERAL NUTRITION; PNEUMONIA; PRIAPISM; PROTEIN DEGRADATION; PROTEIN DIET; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; TESTIS ATROPHY; THERMAL INJURY; TREATMENT DURATION; VIRILIZATION; VOCAL CORD DISORDER; WATER RETENTION; WEIGHT GAIN; WEIGHT REDUCTION; WOUND HEALING;

ADULT; ANABOLIC AGENTS; BODY WEIGHT; BURNS; CLINICAL TRIALS AS TOPIC; HUMANS; NUTRITIONAL SUPPORT; OXANDROLONE; SEVERITY OF ILLNESS INDEX; WOUND HEALING;

EID: 59949088613     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.2.213     Document Type: Review

References (73)

1. Ferrando AA, Wolfe RR. Restoration of hormonal action and muscle protein. Crit Care Med 2007;35(suppl): S630-4.
2. Tredget EE, Yu YM. The metabolic effects of thermal injury. World J Surg 1992;16: 68-79.
3. Gore DC, Chinkes DL, Hart DW, Wolf SE, Herndon DN, Sanford AP. Hyperglycemia exacerbates muscle protein catabolism in burn-injured patients. Crit Care Med 2002;30: 2438-42.
4. Jeschke MG, Mlcak RP, Finnerty CC, et al. Burn size determines the inflammatory and hypermetabolic response [online exclusive article]. Crit Care 2007;11: R90. Available from http://ccforum.com/content/11/4/R90.
5. Jahoor F, Desai M, Herndon DN, Wolfe RR. Dynamics of the protein metabolic response to burn injury. Metabolism 1988;37: 330-7.
6. Mowlavi A, Andrews K, Milner S, Herndon DN, Heggers JP. The effects of hyperglycemia on skin graft survival in the burn patient. Ann Plast Surg 2000;45: 629-32.
7. Wolfe RR. Substrate utilization/insulin resistance in sepsis/trauma. Baillieres Clin Endocrinol Metab 1997;11: 645-57.
8. Bessey PQ, Jiang ZM, Johnson DJ, Smith RJ, Wilmore DW. Posttraumatic skeletal muscle proteolysis: the role of the hormonal environment. World J Surg 1989;13: 465-70.
9. Shea JE, Bowman BM, Miller SC. Alterations in skeletal and mineral metabolism following thermal injuries. J Musculoskelet Neuronal Interact 2003;3: 214-22.
10. Newsome TW, Mason AD Jr, Pruitt BA Jr. Weight loss following thermal injury. Ann Surg 1973;178: 215-17.
11. Yu YM, Tompkins RG, Ryan CM, Young VR. The metabolic basis of the increase in energy expenditure in severely burned patients. J Parenter Enteral Nutr 1999;23: 160-8.
12. Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery 2000;128: 312-19.
13. Murphy KD, Lee JO, Herndon DN. Current pharmacotherapy for the treatment of severe burns. Expert Opin Pharmacother 2003;4: 369-84.
14. Pereira CT, Jeschke MG, Herndon DN. Beta-blockade in burns. Novartis Found Symp 2007;280: 238-48.
15. C ampos AC, G roth AG, Branco AB. Assessment and nutritional aspects of wound healing. Curr Opin Clin Nutr Metab Care 2008;11: 281-8.
16. Hart DW, Wolf SE, Herndon DN, et al. Energy expenditure and caloric balance after burn: increased feeding leads to fat rather than lean mass accretion. Ann Surg 2002;235: 152-61.
17. Btaiche IF, Khalidi N. Metabolic complications of parenteral nutrition in adults, part 1. Am J Health-Syst Pharm 2004;61: 1938-49.
18. Btaiche IF, Khalidi N. Metabolic complications of parenteral nutrition in adults, part 2. Am J Health-Syst Pharm 2004;61: 2050-9.
19. Burke JF, Wolfe RR, Mullany CJ, Mathews DE, Bier DM. Glucose requirements following burn injury: parameters of optimal glucose infusion and possible hepatic and respiratory abnormalities following excessive glucose intake. Ann Surg 1979;190: 274-85.
20. Gramlich L, Kichian K, Pinilla J, Rodych NJ, Dhaliwal R, Heyland DK. Does enteral nutrition compared to parenteral nutrition result in better outcomes in critically ill adult patients? A systematic review of the literature. Nutrition 2004;20: 843-8.
21. Herndon DN, Barrow RE, Stein M, et al. Increased mortality with intravenous supplemental feeding in severely burned patients. J Burn Care Rehabil 1989;10: 309-13.
22. Wasiak J, Cleland H, Jeffery R. Early versus delayed enteral nutrition support for burn injuries. Cochrane Database Syst Rev 2006;(3): CD005489.
23. Saffle JR, Wiebke G, Jennings K, Morris SE, Barton RG. Randomized trial of immune-enhancing enteral nutrition in burn patients. J Trauma 1997;42: 793-800.
24. Bongers T, Griffiths RD. Are there any real differences between enteral feed formulations used in the critically ill? Curr Opin Crit Care 2006;12: 131-5.
25. Berger MM, Shenkin A. Trace element requirements in critic ally ill burne d patients. J Trace Elem Med Bio l 2007;21(suppl 1): 44-8.
26. Demling RH. The role of anabolic hormones for wound healing in catabolic states. J Burns Wounds 2005;4: 60-84.
27. Herndon DN, Barrow RE, Kunkel KR, Broemeling L, Rutan RL. Effect of recombinant human growth hormone on donor- site healing in severely burned children. Ann Surg 1990;212: 424-9.
28. Ziegler TR, Young LS, Ferrari-Baliviera E, Demling RH, Wilmore DW. Use of human growth hormone combined with nutritional support in a critical care unit. J Parenter Enteral Nutr 1990;14: 574-81.
29. Knox J, Demling R, Wilmore D, Sarraf P, Santos A. Increased survival after major thermal injury: the effect of growth hormone therapy in adults. J Trauma 1995;39: 526-30.
30. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341: 785-92.
31. Zhang XJ, Chinkes DL, Irtun O, Wolfe RR. Anabolic action of insulin on skin wound protein is augmented by exogenous amino acids. Am J Physiol Endo crino l Metab 2 002; 282: E1308-15.
32. Jahoor F, Herndon DN, Wolfe RR. Role of insulin and glucagon in the response of glucose and alanine kinetics in burn-injured patients. J Clin Invest 1986;78: 807-14.
33. Jahoor F, Shangraw RE, Miyoshi H, Wallfish H, Herndon DN, Wolfe RR. Role of insulin and glucose oxidation in mediating the protein catabolism of burns and sepsis. Am Physiol 1989;257: E323-31.
34. Gore DC, Wolf SE, Herndon DN, Wolfe RR. Relative influence of glucose and insulin on peripheral amino acid metabolism in severely burned patients. J Parenter Enteral Nutr 2002;26: 271-7.
35. Thomas SJ, Morimoto K, Herndon DN, et al. The effect of prolonged euglycemic hyperinsulinemia on lean body mass after severe burn. Surgery 2002;132: 341-7.
36. Ferrando AA, Chinkes DL, Wolf SE, Matin S, Herndon DN, Wolfe RR. A submaximal dose of insulin promotes net skeletal muscle protein synthesis in patients with severe burns. Ann Surg 1999;229: 11-18.
37. Pierre EJ, Barrow RE, Hawkins HK, et al. Effects of insulin on wound healing. J Trauma 1998;44: 342 5.
38. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345: 1359 67.
39. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. Crit Care Med 2007;35: 2262 7.
40. Ferrando AA, Sheffield-Moore M, Wolf SE, Herndon DN, Wolfe RR. Testosterone administration in severe burns ameliorates muscle catabolism. Crit Care Med 2001;29: 1936 42.
41. Indevus Pharmaceuticals, Inc. Delatestryl (testosterone enanthate, solution for injection USP, CIII) package insert. Lexington, MA; 2005.
42. Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 2004;64: 725 50.
43. Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn. Ann Surg 2001;233: 556 64.
44. Wolf SE, Thomas SJ, Dasu MR, et al. Improved net protein balance, lean mass, and gene expre ssio n changes with oxandrolone treatment in the severely burned. Ann Surg 2003;237: 801 10.
45. Saggers GC, Allison BS, Levinson HD, Kramer MD, Mackay DR, Ehrlich HP. The influe nce of the anabolic agent oxandrolone upon the expression of procollagen types I and III mRNA in human fibroblasts cultured on collagen or plastic. Wounds 2001;13: 66-71.
46. Savient Pharmaceuticals, Inc. Oxandrin (oxandrolone tablets, USP, CIII) package insert. East Brunswick, NJ; 2006.
47. Karim A, Ranney RE, Zagarella J, Maibach HI. Oxandrolone disposition and metabolism in man. Clin Pharmacol Ther 1973;14: 862-9.
48. Goldman AG, Zarday Z. Effects of oxandrolone in advanced renal insufficiency: report of metabolic balance studies. N Y StateJ Med 1973;73: 316-19.
49. Jeschke MG, Finnerty CC, Suman OE, Kulp G, Mlcak RP, Herndon DN. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic responses during the acute phase postburn. Ann Surg 2007;246: 351 60.
50. Thomas S, Wolf SE, Murphy KD, Chinkes DL, Herndon DN. The long-term effect of oxandrolone on hepatic acute phase proteins in severely burned children. J Trauma 2004;56: 37 44.
51. Murphy KD, Thomas S, Mlcak RP, Chinkes DL, Klein GL, Herndon DN. Effects of long-term oxandrolone administration in severely burned children. Surgery 2004;136: 219 24.
52. Przkora R, Jeschke MG, Barrow RE, et al. Metabolic and hormonal changes of severely burned children receiving long- term oxandrolone treatment. Ann Surg 2005;242: 384 9.
53. Przkora R, Herndon DN, S uman OE. The effects o f oxandrolone and exercise on muscle mass and function in children with severe burns. Pediatrics 2007;119: e109 16.
54. Demling RH, Orgill DP. The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care 2000;15: 12-17.
55. Wolf S E, Edelman LS, Kemalyan N, et al. Effects of oxandrolone on outcome measures in the severely burned: a multicenter prospective randomized double-blind trial. J Burn Care Res 2006;27: 131-9.
56. Demling RH, Desanti L. The anabolic steroid, oxandrolone, reverses the wound healing impairment in corticosteroid- dependent burn and wound patients. Wounds 2001;13: 203-8.
57. Demling RH, Desanti L. The beneficial effects of the anabolic steroid oxandrolone in the geriatric burn population. Wounds 2003;15: 54-8.
58. Demling RH. Co mparison of the anabolic effects and complications of human growth hormone and the testosterone analog, oxandrolone, after severe burn injury. Burns 1999;25: 215-21.
59. Demling RH, DeSanti L. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J Trauma 1997;43: 47-51.
60. Demling RH, DeSanti L. Oxandrolone induced lean mass gain during recovery from severe burns is maintained after discontinuation of the anabolic steroid. Burns 2003;29: 793-7.
61. Demling RH, DeSanti L. The rate of restoration of body weight after burn injury, using the anabolic agent oxandrolone, is not age dependent. Burns 2001;17: 46-51.
62. Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care 1998;11: 277-85.
63. Wicke C, Halliday B, Allen D, et al. Effects of steroids and retinoids on wound healing. Arch Surg 2000;135: 1265-70.
64. Bessey PQ, Arons RR, DiMaggio CJ, Yurt RW. The vulnerabilities of age: burns in children and older adults. Surgery 2006;140: 705-17.
65. Lionelli G T, Pickus EJ, Beckum O K, DeC oursey RL, Korentager RA. A three decade analysis of factors affecting burn mortality in the elderly. Burns 2005;31: 958-63.
66. Farrell RT, G amelli RL, Aleem RF, Sinacore JM. The relationship of body mass index and functional outcomes in patients with acute burns. J Burn Care Res 2008;29: 102-8.
67. McC owen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001;17: 107-24.
68. Klein GL, Herndon DN, Rutan TC, et al. Bone disease in burn patients. J Bone Miner Res 1993;8: 337-45.
69. Murphy KD, Thomas S, Mlcak RP, Chinkes DL, Klein GL, Herndon DN. Effects of long-term oxandrolone administration in severely burned children. Surgery 2004;136: 219-24.
70. Przkora R, Jeschke MG, Barrow RE, et al. Metabolic and hormonal changes of severely burned children receiving long- term oxandrolone treatment. Ann Surg 2005;242: 384-9.
71. McCullough M, Namias N, Schulman C, et al. Incidence of hepatic dysfunction is equivalent in burn patients receiving oxandrolone and controls. J Burn Care Res 2007;28: 412-20.
72. Bulger EM, Jurkovich GJ, Farver CL, Klotz P, Maier RV. O xandro lone does not improve outcome of ventilator dependent surgical patients. Ann Surg 2004;240: 472-80.
73. Anonymous. Drug topics red book. Montvale, NJ: Thomson, 2008: 529-30.